New therapies and combinations make progress in HER2-positive breast cancer.
Elizabeth Whittington
Advertisement
Articles by Elizabeth Whittington
Research into vaccine therapy for cancer is extending to many cancer types.
Estrogen-only hormone therapy ups breast cancer risk if taken long term.
Data from the phase 3 EMILIA trial shows progression-free survival benefit in metastatic HER2-positive breast cancer patients.
To tackle platinum-resistant ovarian cancer, a French research group added Avastin (bevacizumab) to standard chemotherapy.
Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies for GIST and metastatic colorectal cancer.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
What Patients With Cancer Should Know About Radiation Side Effects
2
Community of Support Available for Patients With Cancer
3
Why Should Patients With Breast Cancer Prioritize Wellness?
4
Moving Forward After Follicular Lymphoma With a New Companion
5
